We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+0.15%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$396M
AUM Growth
+$117M
Cap. Flow
+$131M
Cap. Flow %
33.06%
Top 10 Hldgs %
59.9%
Holding
91
New
22
Increased
27
Reduced
12
Closed
18

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$7.78M
2
ARYE
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
+$6.98M
3
OCUL icon
Ocular Therapeutix
OCUL
+$5.62M
4
BBIO icon
BridgeBio Pharma
BBIO
+$5.6M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$4.42M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$6.29M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$3.74M
3
XLRN
Acceleron Pharma
XLRN
+$2.57M
4
MGNX icon
MacroGenics
MGNX
+$2.15M
5
EPIX
ESSA Pharma
EPIX
+$2M

Sector Composition

Rank Sector Weight
1 Healthcare 55.88%
2 Financials 4.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$88M 22.22%
700,000
+500,000
+250% +$64.4M
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$42.9M 10.84%
+100,000
New +$44.1M
BBIO icon
3
BridgeBio Pharma
BBIO
$15.9B
$30.7M 7.75%
654,435
+104,435
+19% +$5.6M
VINC
4
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$16.3M 4.1%
50,250
+8,334
+20% +$2.43M
MORF
5
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$15.3M 3.87%
270,755
+24,554
+10% +$1.49M
NARI
6
DELISTED
Inari Medical, Inc. Common Stock
NARI
$10.9M 2.77%
135,000
+50,000
+59% +$4.2M
KURA icon
7
Kura Oncology
KURA
$964M
$9.93M 2.51%
530,000
+105,000
+25% +$1.98M
SWTX
8
DELISTED
SpringWorks Therapeutics
SWTX
$7.99M 2.02%
126,013
+101,013
+404% +$7.78M
CERE
9
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$7.67M 1.94%
259,966
+59,966
+30% +$1.68M
OCUL icon
10
Ocular Therapeutix
OCUL
$1.96B
$7.5M 1.89%
750,000
+500,000
+200% +$5.62M
ARYE
11
DELISTED
ARYA Sciences Acquisition Corp V Class A Ordinary Shares
ARYE
$6.94M 1.75%
+702,500
New +$6.98M
ACRS icon
12
Aclaris Therapeutics
ACRS
$793M
$6.3M 1.59%
350,000
+75,000
+27% +$1.2M
XLRN
13
DELISTED
Acceleron Pharma
XLRN
$6.08M 1.54%
35,350
-19,650
-36% -$2.57M
ARYD
14
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$6.04M 1.52%
600,000
-100,000
-14% -$1.01M
NAUT icon
15
Nautilus Biotechnolgy
NAUT
$221M
$5.99M 1.51%
975,000
+75,000
+8% +$598K
ASND icon
16
Ascendis Pharma A/S
ASND
$17.1B
$5.72M 1.45%
35,910
+15,910
+80% +$2.18M
ZNTL icon
17
Zentalis Pharmaceuticals
ZNTL
$364M
$5.17M 1.3%
77,500
-64,918
-46% -$3.74M
MRTX
18
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.87M 1.23%
+27,500
New +$4.42M
TVTX icon
19
Travere Therapeutics
TVTX
$5.27B
$4.85M 1.22%
+200,000
New +$3.67M
FLNA
20
PUT
Filana Therapeutics
FLNA
$51.2M
$4.66M 1.18%
+75,000
New +$6.26M
CRIS icon
21
Curis
CRIS
$9.02M
$4.5M 1.14%
1,438
-187
-12% -$584K
CYTK icon
22
Cytokinetics
CYTK
$10.9B
$4.47M 1.13%
125,000
+55,000
+79% +$1.62M
ESTA icon
23
Establishment Labs
ESTA
$2.72B
$4.29M 1.08%
60,000
+40,000
+200% +$2.95M
EDIT icon
24
PUT
Editas Medicine
EDIT
$457M
$4.11M 1.04%
+100,000
New +$5.48M
IOVA icon
25
Iovance Biotherapeutics
IOVA
$2.23B
$3.7M 0.93%
150,000
+50,000
+50% +$1.18M
1
2 3 4

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Affinity Asset Advisors held 91 positions worth $396M, up 42% from $279M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Affinity Asset Advisors deployed $131M of net new capital in Q3 2021, opening 22 new positions and adding to 27 existing holdings. Its largest new stake was ARYA Sciences Acquisition Corp V Class A Ordinary Shares: 702,500 shares worth $6.94M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 68% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Zentalis Pharmaceuticals, an estimated $3.74M trimmed.

  • Affinity Asset Advisors's largest Q3 2021 buy was ARYA Sciences Acquisition Corp V Class A Ordinary Shares: 702,500 shares worth $6.94M.
  • Affinity Asset Advisors added most to SpringWorks Therapeutics in Q3 2021, an estimated $7.78M increase.
  • Affinity Asset Advisors's biggest Q3 2021 reduction was Zentalis Pharmaceuticals, cutting an estimated $3.74M.
  • Affinity Asset Advisors fully exited Protagonist Therapeutics in Q3 2021, selling an estimated $6.29M.
  • Affinity Asset Advisors's ten largest holdings make up 60% of its $396M portfolio in Q3 2021.
  • Affinity Asset Advisors opened 22 new positions and closed 18 in Q3 2021.
  • Affinity Asset Advisors's portfolio value rose 42% quarter-over-quarter to $396M.

Based on Affinity Asset Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.